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 Cancer is the second leading cause of death globally and was 
responsible for 8,8 million deaths in 2015. Approximately 70% of 
deaths from cancer occur in low- and middle-income countries. The war 
on cancer has been fought with three tools – surgery (cut), radiation 
therapy (burn) including radiotherapy and bracytherapy, and also 
chemotherapy (poison). Cancer therapy has increased life expectancy of 
patients but each treatment modality has its own effects, complications 
and toxicity. Moreover we have found a new effective method to fight 
cancer, that is, Boron Neutron Capture Therapy (BNCT). Boron Neutron 
Capture Therapy (BNCT) has for many decades been advocated as an 
innovative form of radiotherapy that, in principle, has the potential to be 
the ideal form of treatment for many types of cancers. This research’s 
aim is the characterising neutron of BNCT water phantom based on 30 
MeV cyclotron using PHITS computational code. The result from the 
simulation is that thickness of the water phantom, related to flux 
neutron.  
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1. INTRODUCTION 
Cancer is the second leading cause of 
death globally and was responsible for 8,8 
million deaths in 2015. Globally, nearly 1 in 6 
deaths is due to cancer. Not only it in the same 
year cancer also be a leading causes of death 
worldwide. Approximately 70% of deaths from 
cancer occur in low and middle-income 
countries. The most common causes of cancer 
death are cancers of the lung (1.69 million 
deaths) , liver (788 000 deaths), colorectal (774 
000 deaths), stomach (754 000 deaths) and 
breast (571 000 deaths).[1] Meanwhile 14.1 
million new cancer cases and 8.2 million 
cancer deaths occured in 2012 worldwide, with 
the most common cancer death from lung 
cancer (1.6 million deaths), liver cancer (745 
000 deaths), stomach cancer (723 000 deaths), 
colorectal cancer (693 000 deaths), and breast 
cancer (522 000 deaths).[2]  
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 The data shows that there had been  
increased cancer causes in the world. Although 
Indonesia is not included in the 50 biggest 
countries whith the highest cancer death rate, 
but in 2012 Indonesia had high enough cancer 
deaths for 1.551 million of the total Indonesian 
population of 247 million. [3] The prevalence 
of Indonesian cancer causes was 1,4 ‰, with 
the highest prevalence in DI Yogyakarta (4,1 
‰), following Central  Java (2,1 ‰), Bali (2 
‰), Bengkulu and DKI Jakarta at 1,9 ‰. [4] 
 Cancer is a group of diseases 
characterized by the uncontrolled growth and 
speread of abnormal cells. If the spread is not 
controlled, it can result in death. [5] But there 
is no type of cancer from which some people 
have not recovered. The road to recovery 
generally is not very easy and requires real 
determination.[6] 
 The war on cancer has been fought with 
three tools – surgery (cut), radiation therapy 
(burn) including radiotherapy and 
bracytherapy, and also chemotherapy 
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(poison).[7] Cancer therapy has increased life 
expectancy of patients but Each treatment 
modality has its own effects, complications and 
toxicity ; [8] such as cardiac toxicity following 
radiotherapy that can manifest itself as 
arrhythmias, pericarditis, congestive heart 
disease, ischemic heart disease (myocardial 
infarctions), or valvular disease with the 
pathogenesis of these entities suggested to be 
fibrosis/damage of the AV node and 
conduction system, inflammation, fibrosis, 
accelerated atherosclerosis, and fibrosis 
respectively.[9] In collon cancer operations can 
cause difficult lymphatic to drainage after 
surgery [10] and laryngectomy is often 
required, which inevitably results in permanent 
tracheostomy and loss of the natural voice. [11] 
Furthermore, some  cancer therapy can change 
be a more chronic disease. For example a 
benign tumor can be malignant. Moreover a 
new effective method to fight cancer, that is, 
Boron Neutron Capture Therapy (BNCT). [12] 
Boron Neutron Capture Therapy (BNCT) has 
for many decades been advocated as an 
innovative form of radiotherapy that, in 
principle, has the potential to be the ideal form 
of treatment for many types of cancers.[13] 
1.1. Boron Neutron Capture Therapy 
(BNCT) 
Boron neutron capture therapy (BNCT) is 
an emerging cancer treatment modality that 
utilizes the neutron capture reaction of boron-
10 (10B) and subsequent nuclear fission 
reaction to produce cellular death. [14] The 
result of this reaction is 10 B (n,α)7Li which 
has high LET ( Linier Energy Transfer) with α 
particle 150 keVµm-1 and the 7Li  175 
keVµm-1 . [17][18] 
Dosimetry of BNCT is very complicated 
because of the presence of different dose 
components including oron dose (DB): The 
dose from 10B(n,α)7Li reaction; gamma dose 
(Dg): The dose from the neutron beam and 
1H(nth,γ)2H reaction; thermal neutron dose 
(Dth): The dose resulting from thermal neutron 
capture in nitrogen 14N(nth, p)14C; fast 
neutron dose (Df): The dose from the 1H(n, 
n’)2H reaction.[15] Besides the dose delivered 
to the target organ in a BNCT treatment, the 
doses deposited in the remaining organs may 
induce secondary cancer risk.[16] Moreover, 
we have to calculate more about the neutron 
fluks. Because of calculation of the fluks we 
have to make a simulation using Particle and 
Heavy Ion Transport Code System (PHITS). 
1.2. Cyclotron- Based Neutron Source 
In 2006 KURRI and SHI started 
development of the accelerator based neutron 
source for BNCT. In order to get high flux of 
epithermal neutrons, a combination of 30 MeV 
proton beams and a beryllium target was 
selected after the feasibility study. The neutron 
source consists of a cyclotron as the 
accelerator, a beam transport system and an 
irradiation and treatment system. Figure 1 
shows the layout of the neutron source. The 
source was installed in December 2008 at the 
Innovation Research Laboratory in KURRI. 
The main equipments were installed in the area 
of 18 m long and 15 m wide excluding power 
supply rooms.[19] 
This KURRI project has to deal with a 
very hard neutron spectrum. The current status 
have target beam energi 30 MeV, beam current 
1 mA.[20] 
 
Figure 1. Layout of neutron source. 
1.3. Particle Heavy Ion Transport System 
(PHITS)  
PHITS have been used for several 
medicine aplications such as radiation dose 
therapy estimation and tomograph investigation 
computer based. Several reasons for using 
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PHITS is that it has high acuration, less 
computation time, less suspending file, 
repairing fault in MCNPX, detail investigation, 
can simulate all the kinds of particle transport 
and is used in various calculating 
microdosimetri applications; such as bilogy 
dose estimation from the multiplication betwen 
RBE and phisycs dose.[21][22][23] 
2. MATERIALS AND METHODS 
Legal Requirement 
The designing to know the neutron 
characterization of water phantom BNCT based 
on 30 MeV cyclotron have been done using a 
set of programs PHITS. 
The procedure of the reasearch 
implementation is formulated in a flow chart 
shown by figure 2.  
 
Fig 2. Fluks calculation algorithm on PHITS 
programs.  
 
 This reaserch’s main specification using 
cyclotron 30 MeV based is shown on table 1. 
3. RESULTS AND DISCUSSION 
Neutron characterization has been 
designed using PHITS. HM-30 cyclotron 
succesfully accelerated the 30 MeV proton 
beam which is limited by the radiation 




Fig 3. The design neutron characterization using 
PHITS. 
 
The water phantom was positioned in y 
axis from -5.000 cm to 5.000 cm and the 
energy from 0.000 MeV to 1.000 MeV.  
 Results after the program had been 
running are shown in figure 4,5,6,7,8,and 9. 
 
Fig 4. Fluks characterization in region 1. 
 
Start 
Surface card, cell card, and data card 
Calculating fluks neutron (running) 
Output 
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Fig 5. Fluks characterization in region 2. 
 
Fig 6. Fluks characterization in region 3. 
 
 
Fig 7. Fluks characterization in region 4. 
 
 
Fig 8. Fluks characterization in region 5. 
 
 
Fig 9. Fluks characterization in region 6. 
 
4. CONCLUSION AND REMARKS 
The result from the simulation is that the 
ticker of water phantom has smaller neutron 
flux.  
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